287 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
.
11.14 Governing Law; Jurisdiction; Etc.
11.15 Waiver of Jury Trial.
11.16 Subordination.
11.17 No Advisory or Fiduciary Responsibility.
11.18 … EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
“Electronic Record
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Sep 23
Departure of Directors or Certain Officers
8:38am
of Global Regulatory Affairs at Alexion Pharma International from June 2016 until January 2023 and in various roles of increasing responsibility at Alexion
8-K
EX-10.1
cu74i4rn
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
S-3ASR
97r61vu
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-1.2
5sbkp0r35k7xurnwp
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-4.3
i2i6jcujvc 5k
30 Sep 22
Automatic shelf registration
4:17pm
425
o4za 8jn18fo86u
24 Mar 22
Business combination disclosure
9:09am
8-K
gshiqf
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
8zyzvqwt6
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-10.1
tbqqgl
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.1
k5fntscokyn4r i3hj
24 Mar 22
Entry into a Material Definitive Agreement
9:08am